GlassScriptPhysician profile
Aqeel Khan
NPI 1629046735
$2,458.94
in general payments reported to CMS, 2019-2025
23 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $120 · 2021: $126 · 2022: $307 · 2023: $578 · 2024: $483 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $400.10 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $354.57 | 2019-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $270.11 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.46 | 2021-2025 | Caplyta |
| Lundbeck LLC | $210.98 | 2019-2025 | Rexulti |
| Indivior INC. | $178.10 | 2022-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $136.55 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $133.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $101.82 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $76.13 | 2019-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $60.57 | 2024-2025 | Auvelity |
| Acadia Pharmaceuticals INC | $55.65 | 2020 | |
| Neurocrine Biosciences, INC. | $41.07 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $33.38 | 2022-2023 | Qelbree |
| Lilly USA, LLC | $28.06 | 2023 | Amyvid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $26.46 | 2025 | Erzofri Extended-Release |
| Uswm, LLC | $23.02 | 2021 | |
| Owp Pharmaceuticals, INC. | $19.84 | 2022 | |
| Corium, LLC | $19.28 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $18.96 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.37 | 2022 | |
| Almatica Pharma LLC | $17.83 | 2022 | |
| Orexo US, INC. | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aqeel Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.